Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation
Molecules · 15.10.2024 · 29 (20) · 4881
DOI: 10.3390/molecules29204881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 15.10.2024. Verfasst von Yu-E Lian und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China. Hauptthemen laut MEDLINE: PPAR gamma, Molecular Dynamics Simulation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Thiazolidinediones (TZDs) including rosiglitazone and pioglitazone function as peroxisome proliferator-activated receptor gamma (PPARγ) full agonists, which have been known as a class to be among the most effective drugs for the treatment of type 2 diabetes mellitus (T2DM). However, side effects of TZDs such as fluid retention and weight gain are associated with their full agonistic activities toward PPARγ induced by the AF-2 helix-involved “locked” mechanism. Thereby, this study aimed to obtain novel PPARγ partial agonists without direct interaction with the AF-2 helix. Through performing virtual screening of the Targetmol L6000 Natural Product Library and utilizing molecular dynamics (MD) simulation, as well as molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) analysis, four compounds including tubuloside b, podophyllotoxone, endomorphin 1 and paliperidone were identified as potential PPARγ partial agonists. An in vitro TR-FRET competitive binding assay showed podophyllotoxone displayed the optimal binding affinity toward PPARγ among the screened compounds, exhibiting IC50 and ki values of 27.43 µM and 9.86 µM, respectively. Further cell-based transcription assays were conducted and demonstrated podophyllotoxone’s weak agonistic activity against PPARγ compared to that of the PPARγ full agonist rosiglitazone. These results collectively demonstrated that podophyllotoxone could serve as a PPARγ partial agonist and might provide a novel candidate for the treatment of various diseases such as T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Program of Guangzhou
- Plan on Enhancing Scientific Research in GMU, the College Students’ Innovation Training Program
- Undergraduate Teaching Quality and Teaching Reform Project Construction Project of Guangdong Province in 2022-“Guangzhou Medical University and Xinbaotang Comp…
Zitieren
APA
Lian, Y. E., Wang, M., Ma, L., Yi, W., Liao, S., Gao, H., & Zhou, Z. (2024). Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation. Molecules, 29(20), 4881. https://doi.org/10.3390/molecules29204881
Vancouver
Lian YE, Wang M, Ma L, Yi W, Liao S, Gao H, et al. Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation. Molecules. 2024;29(20):4881. doi:10.3390/molecules29204881
BibTeX
@article{Lian2024,
author = {Lian, Yu-E and Wang, Mei and Ma, Lei and Yi, Wei and Liao, Siyan and Gao, Hui and Zhou, Zhi},
title = {Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation},
journal = {Molecules},
year = {2024},
volume = {29},
number = {20},
pages = {4881},
doi = {10.3390/molecules29204881}
}
EUVIMED